Prince Pharmaceutical Co (ROCO:6935) Interest Expense: NT$-10 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6935 Prince Pharmaceutical Co Ltd ROCO:6935
61 GF Score
Price NT$30.25
GF Value NT$42.17
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prince Pharmaceutical Co Interest Expense?

Prince Pharmaceutical Co ROCO:6935 +4.85% 61 Interest Expense is NT$-10 Mil as of Dec. 2025. GuruFocus rates ROCO:6935 with a GF Score™ of 61/100 and a GF Value™ of NT$42.17 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Prince Pharmaceutical Co's interest expense for the six months ended in Dec. 2025 was NT$ -5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Prince Pharmaceutical Co's Operating Income for the six months ended in Dec. 2025 was NT$ 84 Mil. Prince Pharmaceutical Co's Interest Expense for the six months ended in Dec. 2025 was NT$ -5 Mil. Prince Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2025 was 17.92. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Prince Pharmaceutical Co  (ROCO:6935) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Prince Pharmaceutical Co's Interest Expense for the six months ended in Dec. 2025 was NT$-5 Mil. Its Operating Income for the six months ended in Dec. 2025 was NT$84 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was NT$354 Mil.

Prince Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*84.455/-4.713
=17.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Prince Pharmaceutical Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Prince Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prince Pharmaceutical Co Interest Expense Chart

Prince Pharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -7.55 -8.94 -10.46 -10.27 -9.58

Prince Pharmaceutical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.24 -5.15 -5.12 -4.87 -4.71
ROCO:6935
61GF Score
Prince Pharmaceutical Co Ltd ROCO:6935
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prince Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of NT$-10 Mil mean?
Prince Pharmaceutical Co (ROCO:6935) has a Interest Expense of NT$-10 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Prince Pharmaceutical Co and its competitors.
Is Prince Pharmaceutical Co's Interest Expense too high?
Prince Pharmaceutical Co's current Interest Expense is NT$-10 Mil. Overall, Prince Pharmaceutical Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's Interest Expense compare to ZTS and UTHR?
Prince Pharmaceutical Co's Interest Expense of NT$-10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Prince Pharmaceutical Co and its competitors. Prince Pharmaceutical Co's current Interest Expense is NT$-10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$42.17, compared to a current price of NT$30.25 — trading 28.3% below its estimated fair value. The current Interest Expense is NT$-10 Mil. Prince Pharmaceutical Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current Interest Expense is NT$-10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?

Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$30.25 is trading 28.3% below its estimated GF Value™ of NT$42.17. GuruFocus considers Prince Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for ROCO:6935:

  • Interest Expense: NT$-10 Mil
  • GF Value™: NT$42.17 vs. price of NT$30.25 (28.3% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prince Pharmaceutical Co Business Description

Address Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
61GF Score

Get the complete analysis for ROCO:6935

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.25
Price
NT$42.17
GF Value